ASH 2023 | Canakinumab with darbepoetin in patients with LR-MDS who are ESA-refractory
Jeffrey Lancet, MD, Moffitt Cancer Center, Tampa, FL, discusses findings from a Phase I trial (NCT04798339) evaluating the combination of interleukin 1β (IL-1β) neutralizing antibody canakinumab with darbepoetin in the treatment of patients with lower-risk myelodysplastic syndromes (LR-MDS) who are refractory to erythropoietin stimulating agents (ESA). The combination inhibited inflammasome activation, hypothesized as a critical driver of MDS pathogenesis, although this did not translate to clinical responses. A dose of 300mg of canakinumab was well-tolerated and is recommended for Phase II trials. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Jazz, The Dedham Group, Tegus, Servier, Peer Voice, Novartis, MEDTalks, MD Anderson, AbbVie Inc., Atheneum, BerGenBio / DAVA Oncology, Boxer Capital, Celgene, Globe Life Sciences, Jasper Therapeutics
Research Funding: Celgene
